Highlights: Reduces operating expenses Update on MagSense® HER2 program MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it
1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan
SINGAPORE, and San Diego, California – Prestige Biopharma, a biopharmaceutical company specializing in innovative antibody therapies, with a strong dedication to tackling pancreatic cancer, and Imagion
Dear Imagion Biosystems Shareholders, It has been an incredible first month ramping up as Chief Executive Officer with Team Imagion Biosystems. With this quarter’s 4C
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has
Highlights Study achieves enrolment target Study to formally close to new enrolments on 31 July Study results support further clinical development as MRI imaging agent
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to announce it has appointed Isaac
Australasian Biotechnology | Vol 33 Number 1 Imagion authored a white paper, published in the April issue of Australasian Biotechnology, discussing current medical imaging technologies,
Highlighting our dedicated employees who bring both their experience and passions to Imagion Biosystems: What experience do you bring prior to joining IB? I
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance